JPWO2024204440A5 - - Google Patents

Info

Publication number
JPWO2024204440A5
JPWO2024204440A5 JP2025511074A JP2025511074A JPWO2024204440A5 JP WO2024204440 A5 JPWO2024204440 A5 JP WO2024204440A5 JP 2025511074 A JP2025511074 A JP 2025511074A JP 2025511074 A JP2025511074 A JP 2025511074A JP WO2024204440 A5 JPWO2024204440 A5 JP WO2024204440A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
sequence represented
seq
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2025511074A
Other languages
English (en)
Japanese (ja)
Other versions
JP7747395B2 (ja
JPWO2024204440A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2024/012454 external-priority patent/WO2024204440A1/ja
Publication of JPWO2024204440A1 publication Critical patent/JPWO2024204440A1/ja
Publication of JPWO2024204440A5 publication Critical patent/JPWO2024204440A5/ja
Priority to JP2025150483A priority Critical patent/JP2025183331A/ja
Application granted granted Critical
Publication of JP7747395B2 publication Critical patent/JP7747395B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2025511074A 2023-03-28 2024-03-27 抗体、核酸、細胞、及び医薬 Active JP7747395B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025150483A JP2025183331A (ja) 2023-03-28 2025-09-10 抗体、核酸、細胞、及び医薬

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023051486 2023-03-28
JP2023051486 2023-03-28
PCT/JP2024/012454 WO2024204440A1 (ja) 2023-03-28 2024-03-27 抗体、核酸、細胞、及び医薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025150483A Division JP2025183331A (ja) 2023-03-28 2025-09-10 抗体、核酸、細胞、及び医薬

Publications (3)

Publication Number Publication Date
JPWO2024204440A1 JPWO2024204440A1 (https=) 2024-10-03
JPWO2024204440A5 true JPWO2024204440A5 (https=) 2025-08-05
JP7747395B2 JP7747395B2 (ja) 2025-10-01

Family

ID=92905743

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2025511074A Active JP7747395B2 (ja) 2023-03-28 2024-03-27 抗体、核酸、細胞、及び医薬
JP2025150483A Pending JP2025183331A (ja) 2023-03-28 2025-09-10 抗体、核酸、細胞、及び医薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025150483A Pending JP2025183331A (ja) 2023-03-28 2025-09-10 抗体、核酸、細胞、及び医薬

Country Status (7)

Country Link
EP (1) EP4692121A1 (https=)
JP (2) JP7747395B2 (https=)
KR (1) KR20260011663A (https=)
CN (1) CN120092019A (https=)
AU (1) AU2024247601A1 (https=)
IL (1) IL323505A (https=)
WO (1) WO2024204440A1 (https=)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
DK0584348T3 (da) 1992-03-11 2005-09-19 Powderject Vaccines Inc Genetisk vaccine mod immundefektvirusser
US7087372B2 (en) * 2001-01-18 2006-08-08 Idexx Laboratories, Inc. Compositions and methods for detection of Ehrlichia canis and Ehrlichia chaffeensis antibodies
WO2003066824A2 (en) * 2002-02-07 2003-08-14 Aventis Behring Gmbh Albumin-fused kunitz domain peptides
US7790446B2 (en) 2005-02-11 2010-09-07 Kosagen Cell Factory Oü Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products
EP2480671B8 (en) 2009-09-22 2015-10-28 ProBioGen AG Process for producing molecules containing specialized glycan structures
EP2623592B1 (en) 2010-09-28 2019-05-15 NB Health Laboratory Co. Ltd. Anti-human ccr7 antibodies, hybridoma, medicinal composition, and antibody-immobilized carrier
AU2012322721B2 (en) * 2011-10-11 2016-05-05 Vaccinex, Inc. Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability
DK3334457T3 (da) 2015-08-10 2020-09-21 Pepmab B V Humaniserede anti-CCR7-receptorantistoffer
WO2020138489A1 (ja) * 2018-12-27 2020-07-02 塩野義製薬株式会社 新規抗ｃｃｒ８抗体
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
WO2022004760A1 (ja) 2020-06-30 2022-01-06 塩野義製薬株式会社 抗ｃｃｒ８抗体と化学療法剤の併用

Similar Documents

Publication Publication Date Title
ES3031002T3 (en) T cell recruiting polypeptides based on tcr alpha/beta reactivity
EP3049439B1 (en) Bispecific nanobodies
JP2020127426A5 (https=)
RU2441005C2 (ru) Новые пиразолопиримидины как ингибиторы циклинзависимых киназ
IL302078A (en) Anti-CCR8 monoclonal antibodies and their uses
JP2022513053A5 (https=)
JP2024075737A5 (https=)
JP2017036297A (ja) Ｃｄ３８を特異的に認識する抗体とシクロホスファミドとを含有する抗腫瘍組合せ
RU2014138039A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
RU2014138038A (ru) Фармацевтическая композиция для лечения профилактики рака
Blaszczak et al. Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma
JP2009505676A5 (https=)
RU2020115713A (ru) Конъюгаты анти-cd71 активируемое антитело - лекарственное средство и способы их применения
JP2022523740A5 (https=)
JP2023518153A5 (https=)
JP2023511417A5 (https=)
JP2022532991A5 (https=)
JP2022526841A5 (https=)
JP2024525916A5 (https=)
JPWO2024204440A5 (https=)
JP2021517588A5 (https=)
CN110177807B (zh) 使用抗MUC1抗体和ErbB抑制剂的抗癌治疗
CN112996540A (zh) 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途
JP7793985B2 (ja) 癌の治療及び／又は予防のための医薬品
JP2022531894A5 (https=)